• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

匐行性脉络膜炎中的三联免疫抑制治疗

Triple agent immunosuppression in serpiginous choroiditis.

作者信息

Hooper P L, Kaplan H J

机构信息

Department of Ophthalmology, University of Western Ontario, London, Canada.

出版信息

Ophthalmology. 1991 Jun;98(6):944-51; discussion 951-2. doi: 10.1016/s0161-6420(91)32198-5.

DOI:10.1016/s0161-6420(91)32198-5
PMID:1866149
Abstract

Serpiginous choroidopathy is a progressive choroidal inflammatory disorder that typically has a variable saltatory course. Response to steroids is uncertain. By using azathioprine, cyclosporine, and prednisone in combination, the authors have observed rapid remission of active disease in five patients. Remissions have been maintained for periods up to 18 months. Because of the synergistic effects of this combination, doses could rapidly be reduced to maintenance levels without reactivation. Disease in two patients recurred immediately after discontinuation of low-dose therapy but was arrested when therapy resumed. Triple agent immunosuppressive therapy is well tolerated and appears to be effective.

摘要

匐行性脉络膜病变是一种进行性脉络膜炎症性疾病,通常病程呈可变的跳跃性。对类固醇的反应尚不确定。通过联合使用硫唑嘌呤、环孢素和泼尼松,作者观察到5例患者的活动性疾病迅速缓解。缓解状态已维持长达18个月。由于这种联合用药的协同作用,剂量可迅速降至维持水平而不会复发。两名患者在低剂量治疗中断后疾病立即复发,但恢复治疗后病情得到控制。三联免疫抑制治疗耐受性良好且似乎有效。

相似文献

1
Triple agent immunosuppression in serpiginous choroiditis.匐行性脉络膜炎中的三联免疫抑制治疗
Ophthalmology. 1991 Jun;98(6):944-51; discussion 951-2. doi: 10.1016/s0161-6420(91)32198-5.
2
Combination of azathioprine and corticosteroids in the treatment of serpiginous choroiditis.硫唑嘌呤与皮质类固醇联合治疗匐行性脉络膜炎。
Can J Ophthalmol. 2006 Apr;41(2):183-9. doi: 10.1139/I06-006.
3
Immunosuppressive therapy in serpiginous choroiditis--case report and brief review of the literature.匐行性脉络膜炎的免疫抑制治疗——病例报告及文献简要综述
Klin Monbl Augenheilkd. 2001 May;218(5):394-7. doi: 10.1055/s-2001-15910.
4
Long-term immunosuppressive treatment of serpiginous choroiditis.匐行性脉络膜炎的长期免疫抑制治疗。
Ocul Immunol Inflamm. 2001 Sep;9(3):153-67. doi: 10.1076/ocii.9.3.153.3962.
5
Serpiginous choroiditis.
Int Ophthalmol Clin. 1996 Winter;36(1):135-43. doi: 10.1097/00004397-199603610-00014.
6
Serpiginous choroiditis.匐行性脉络膜炎。
Br J Ophthalmol. 1974 Sep;58(9):777-83. doi: 10.1136/bjo.58.9.777.
7
Atypical central lesions in serpiginous choroiditis treated with oral prednisone.口服泼尼松治疗匐行性脉络膜炎中的非典型中心性病变。
Graefes Arch Clin Exp Ophthalmol. 1998 Feb;236(2):154-6. doi: 10.1007/s004170050057.
8
Multimodal Imaging of Serpiginous Choroiditis.匐行性脉络膜炎的多模态成像
Optom Vis Sci. 2017 Feb;94(2):265-269. doi: 10.1097/OPX.0000000000001015.
9
Efficacy of reduced dose of intravitreal triamcinolone acetonide in a case of active serpiginous choroiditis.低剂量玻璃体内注射曲安奈德治疗活动性匐行性脉络膜炎1例的疗效
Indian J Ophthalmol. 2016 Sep;64(9):681-682. doi: 10.4103/0301-4738.194335.
10
Serpiginous choroiditis.匐行性脉络膜炎。
Ophthalmology. 2008 Sep;115(9):1633, 1633.e1-2. doi: 10.1016/j.ophtha.2008.05.009.

引用本文的文献

1
Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis.非感染性和/或免疫介导性脉络膜炎的发病机制、病理生理学及当前免疫调节/免疫抑制治疗
Pharmaceuticals (Basel). 2022 Mar 24;15(4):398. doi: 10.3390/ph15040398.
2
Efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis: a protocol for a multicentre, randomised, parallel three arms, active-controlled, phase III open label with blinded outcome assessment study.甲氨蝶呤、阿达木单抗或二者联合治疗非感染性非前部葡萄膜炎的疗效、安全性和成本效益:一项多中心、随机、平行、三臂、主动对照、开放标签、盲法结局评估的 III 期研究方案。
BMJ Open. 2022 Mar 22;12(3):e051378. doi: 10.1136/bmjopen-2021-051378.
3
Diagnosis and Treatment of Primary Inflammatory Choriocapillaropathies (PICCPs): A Comprehensive Overview.原发性炎症性脉络膜毛细血管病变(PICCPs)的诊断与治疗:全面综述。
Medicina (Kaunas). 2022 Jan 21;58(2):165. doi: 10.3390/medicina58020165.
4
Tuberculosis-related serpiginous choroiditis: aggressive therapy with dual concomitant combination of multiple anti-tubercular and multiple immunosuppressive agents is needed to halt the progression of the disease.结核相关性匐行性脉络膜炎:需要采用多种抗结核药物和多种免疫抑制剂双重联合的积极治疗来阻止疾病进展。
J Ophthalmic Inflamm Infect. 2022 Feb 8;12(1):7. doi: 10.1186/s12348-022-00282-6.
5
Clinicopathology of non-infectious choroiditis: evolution of its appraisal during the last 2-3 decades from "white dot syndromes" to precise classification.非感染性脉络膜炎的临床病理学:过去20至30年间其评估从“白点综合征”到精确分类的演变
J Ophthalmic Inflamm Infect. 2021 Nov 17;11(1):43. doi: 10.1186/s12348-021-00274-y.
6
Classification of Non-Infectious and/or Immune Mediated Choroiditis: A Brief Overview of the Essentials.非感染性和/或免疫介导性脉络膜炎的分类:要点概述
Diagnostics (Basel). 2021 May 24;11(6):939. doi: 10.3390/diagnostics11060939.
7
Classification Criteria for Serpiginous Choroiditis.匐行性脉络膜炎的分类标准。
Am J Ophthalmol. 2021 Aug;228:126-133. doi: 10.1016/j.ajo.2021.03.038. Epub 2021 Apr 15.
8
Chlorambucil combination therapy in refractory serpiginous choroiditis: A cure?苯丁酸氮芥联合疗法治疗难治性匐行性脉络膜炎:能治愈吗?
Am J Ophthalmol Case Rep. 2021 Jan 30;21:101014. doi: 10.1016/j.ajoc.2021.101014. eCollection 2021 Mar.
9
[White dot syndromes : Principles, diagnostics, and treatment].[白点综合征:原理、诊断与治疗]
Ophthalmologe. 2019 Dec;116(12):1235-1256. doi: 10.1007/s00347-019-01012-5.
10
Visual acuity loss and development of ocular complications in white dot syndromes: a longitudinal analysis of 3 centers.白点综合征患者的视力丧失和眼部并发症的发展:3 个中心的纵向分析。
Graefes Arch Clin Exp Ophthalmol. 2019 Nov;257(11):2505-2516. doi: 10.1007/s00417-019-04429-5. Epub 2019 Aug 5.